Lumitin (conbercept) / Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   307 News 


«12345678»
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Changes of plasma nitric oxide, endothelin-1, and blood coagulation following intravitreal conbercept. (Pubmed Central) -  Jan 28, 2022   
    Plasma levels of NO or ET-1 or VEGF did not significantly change from pre-injection levels. Our findings advanced the understanding of mechanism for systemic side effects associated with intravitreal anti-VEGF and emphasized paying more attention to higher risk of possible bleedings for patients following intravitreal conbercept.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma. (Pubmed Central) -  Jan 28, 2022   
    P=N/A
    We recommend intravitreal injections for patients in stages I and II, but for stage III, intracameral injection is better, and trabeculectomy with mitomycin C should be conducted within 2 days after injection to maximally reduce the risk of perioperative hyphema. Trial Registration: ClinicalTrials.gov, identifier NCT03154892.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Anti-inflammatory activities of a new VEGF blocker, Conbercept. (Pubmed Central) -  Jan 27, 2022   
    Conbercept significantly inhibited xylene-induced ear edema. All results indicate that Conbercept exhibits significant inhibition of acute and chronic inflammation.
  • ||||||||||  Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi, Avastin (bevacizumab) / Roche
    Clinical, Review, Journal, Adverse events:  Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. (Pubmed Central) -  Jan 20, 2022   
    Nonetheless, ocular adverse events following anti-VEGF therapy for myopic CNV may develop and these include worsening or new development of myopic traction maculopathy, increased risk of retinal detachment and progression of chorioretinal atrophy. Clinicians should be aware of these potential complications and evaluate them before and after anti-VEGF therapy.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Preclinical, Journal:  A Study on the Drug Concentration in Fellow Eyes After Unilateral Intravitreal Injection of Conbercept Into New Zealand Rabbit Eyes. (Pubmed Central) -  Dec 21, 2021   
    A peak concentration of 102.49 ng/ml was achieved in the venous serum 1 day after intravitreal injection of conbercept, which was 0.08 and 0.5% of those of the maximum conbercept concentrations in the vitreous humor and aqueous humor of the injected eye, respectively, and 41.5 and 41.8% of the maximum conbercept concentrations in the vitreous humor and aqueous humor of the non-injected eye, respectively. In conclusion, after intravitreal injection of 0.5 mg of conbercept into rabbit eyes, very small amounts of conbercept were detected in the fellow non-injected eyes and venous serum.
  • ||||||||||  Review, Journal:  Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Dec 16, 2021   
    Sustained-release anti-VEGF therapies include the ranibizumab Port Delivery System (in phase 3 studies), GB-102 (Phase 2b), OTX-TKI (phase 1), and Durasert (preclinical)...Genetic therapies in phase 1 studies include RGX-314 and ADVM-022, which introduce a viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory, potentially serving as a one-time treatment. Further investigation is warranted for drugs and delivery systems that hope to advance visual outcomes and reduce treatment burden of nAMD.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  Intravitreal Conbercept for Idiopathic Choroidal Neovascularization in Nursing Women. (Pubmed Central) -  Dec 16, 2021   
    After conbercept injection, VEGF levels in breast milk were slightly decreased and did not change significantly in the following week; levels recovered fully by 30 days post-treatment. Intravitreal injection of conbercept shows favorable effectiveness and safety in the treatment of idiopathic CNV in nursing women and does not result in a significant reduction in VEGF in human breast milk.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION. (Pubmed Central) -  Nov 24, 2021   
    Conbercept treatment influenced the concentrations of various inflammatory cytokines and reduced aqueous vascular endothelial growth factor and placental growth factor concentrations. Rebound ME may occur due to disruption of the balance between angiogenic and inflammatory cytokines and an accompanying excess of inflammatory cytokines but not angiogenic cytokines, after antivascular endothelial growth factor therapy.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  Efficacy of Conbercept in the Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia. (Pubmed Central) -  Nov 10, 2021   
    The intravitreal injection of conbercept significantly reduced CRT and the CNV area, inhibited the leakage of CNV, improved the BCVA, increased the response of mfERG amplitude, and restored the retinal function. The intravitreal injection of conbercept can change the morphology and function of the macular in PM-CNV, which is safe and effective for the treatment of PM-CNV.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept. (Pubmed Central) -  Oct 20, 2021   
    There have not been many clinical trials that study conbercept as compared with other currently available anti-VEGF drugs. There is a need for large-scale, well-designed, randomized clinical trials to ensure its long-term safety and efficacy and to determine if it has any advantages over other anti-VEGF agents.
  • ||||||||||  Journal:  New Anti-Vegf Drugs In Ophthalmology. (Pubmed Central) -  Oct 9, 2021   
    This review focuses on 5 new anti-VEGF drugs in advanced stage of clinical development (i.e. phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and advantages of each drug compared to the available molecules are discussed in detail.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Oct 8, 2021   
    Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Review, Journal:  Pipeline therapies for neovascular age related macular degeneration. (Pubmed Central) -  Oct 3, 2021   
    Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA)...Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics. (Pubmed Central) -  Sep 14, 2021   
    A single-dose rAAV8-KH902 treatment at 8 × 10 genome copies (GCs) per cornea dramatically inhibited CoNV for an extended period of time in mouse CoNV models without adverse events, whereas the inhibition of CoNV by a single intrastromal administration of the conbercept drug lasted for only 10-14 days. Overall, our study demonstrated that the treatment of CoNV with a single dose of rAAV8-KH902 via intrastromal administration was safe, effective, and long lasting, representing a novel therapeutic strategy for CoNV.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  A case report: pseudoxanthoma elasticum diagnosed based on ocular angioid streaks and the curative effect of Conbercept treatment. (Pubmed Central) -  Aug 25, 2021   
    To the best of our knowledge, no publications are available on cases in which a vision loss and the normal visual function can be reverted by intravitreal injection with Conbercept. Although PXE is a disease with low incidence and thus no effective cure established, targeted symptomatic treatment can effectively retard the disease progression and improve visual function, such as intravitreal injection with Conbercept.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy. (Pubmed Central) -  Aug 20, 2021   
    Although PXE is a disease with low incidence and thus no effective cure established, targeted symptomatic treatment can effectively retard the disease progression and improve visual function, such as intravitreal injection with Conbercept. Intravitreal conbercept using the "3 + PRN" regimen was effective in the treatment of PCV.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. (Pubmed Central) -  Aug 11, 2021   
    The corticosteroids approach is mainly based on the employment of triamcinolone acetonide, dexamethasone and fluocinolone acetonide molecules...Furthermore, several new molecules are currently under investigation. Intravitreal drugs focus their activity on a wide range of therapeutic targets and are safe and efficacy in managing retinal diseases.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, faricimab (RG7716) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Review, Journal:  Longer-acting treatments for neovascular age-related macular degeneration-present and future. (Pubmed Central) -  Jul 7, 2021   
    Long-lasting treatments provide promising solutions for this unmet need by achieving better results with less mandatory injections. This review aims to cover the current state in this field and also discuss the mechanism of action, data from pivotal trials, and safety profile of long-acting treatments in present and future, going into details about the following agents: Brolucizumab, Faricimab, Abipicar, and Conbercept.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial termination:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) (clinicaltrials.gov) -  Jun 22, 2021   
    P3,  N=1157, Terminated, 
    Intravitreal conbercept injection by three monthly loading doses followed by PRN treatment regimen was safe and efficacious for patients with macular oedema secondary to CRVO through 1-year follow-up. Trial completion date: Jan 2022 --> May 2021 | Active, not recruiting --> Terminated; desired primary endpoint was not met
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial termination, Trial primary completion date:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (clinicaltrials.gov) -  Jun 21, 2021   
    P3,  N=1157, Terminated, 
    It is effective and cost-effective to treat DME by utilizing triamcinolone as an adjunct to the combination of anti-VEGF. Trial completion date: Mar 2022 --> May 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Sep 2020; desired primary endpoint was not met